CASE REPORT

Epstein-Barr Virus-associated Early Gastric Cancer Treated with Endoscopic Submucosal Dissection: A Possible Candidate for Extended Criteria of Endoscopic Submucosal Dissection

Hideo Yanai1, Daisuke Chihara1, Megumi Harano1, Eiki Sakaguchi1, Tomoyuki Murakami2 and Jun Nishikawa3

Abstract:
A 73-year-old man visited our hospital for the treatment of an early gastric cancer (GC) lesion. We performed en bloc resection using endoscopic submucosal dissection (ESD) for his GC lesion. The present GC lesion was Epstein-Barr virus (EBV)-associated poorly differentiated-type adenocarcinoma invading into the submucosal layer. Recently, accumulating data has shown that the risk of lymph node metastasis from early EBV GC without local lymphovascular infiltration is low. The present patient has been in good health for over three years since ESD. Some cases of early EBV GC with invasion into the submucosal layer may be candidates for further extension of the ESD criteria.

Key words: Epstein-Barr virus-associated gastric cancer, endoscopic submucosal dissection

(Intern Med 58: 3247-3250, 2019)
(DOI: 10.2169/internalmedicine.3055-19)

Introduction

Epstein-Barr virus (EBV) association is detected in almost 10% of gastric cancer (GC) lesions. EBV-associated GC (EBV GC) is a distinct subtype of GC with extreme DNA hypermethylation. Many EBV GCs are located in the upper part of the stomach and remnant stomach. EBV GC is mainly poorly differentiated, tumor-infiltrating lymphocyte-rich adenocarcinoma [carcinoma with lymphoid stroma (CLS)] (1-4). The treatment outcome of advanced EBV GC is reported to be better than that of EBV-negative GC. The risk for lymph node metastasis (LNM) of early EBV GC is also reported to be lower than that for EBV-negative early GC (5-7).

Currently, less-invasive endoscopic submucosal dissection (ESD) is widely used for early GC worldwide (8). However, poorly differentiated GC lesions with invasion into the submucosal layer are an indication for surgical operation with lymph node dissection because of the risk of LNM (9). Recently, further extension of the criteria for ESD for early GC has been suggested (10). EBV GC is a distinct subtype with a low risk of LNM. Therefore, further extension of the criteria for early EBV GC should be discussed.

We herein report a case of early EBV GC treated with ESD and discuss the further extension of the ESD criteria.

Case Report

A 73-year-old man visited our hospital for the further examination and treatment of his second early GC lesion. His initial GC lesion had been a differentiated-type intramucosal one and had been curatively resected at another hospital by endoscopic mucosal resection. He had been Helicobacter pylori-positive but received eradication therapy at his previous hospital.

Seven months after endoscopic resection, another GC lesion was detected by follow-up esophagogastroduodenoscopy.

1Department of Clinical Research, Department of Gastroenterology & Hepatology, National Hospital Organization Kannon Medical Center, Japan
2Department of Pathology, National Hospital Organization Kannon Medical Center, Japan
3Department of Laboratory Science, Yamaguchi University Graduate School of Medicine, Japan
Received for publication March 22, 2019; Accepted for publication June 12, 2019
Correspondence to Dr. Hideo Yanai, yanai.hideo.mu@mail.hosp.go.jp
The pathological type was CLS, and lymphovascular infiltration was negative according to D2-40 immune-staining and Elastic van Gieson (EVG) staining. A portion of the lesion was differentiated-type adenocarcinoma. Cancer lesions of mixed histological type in the stomach carry a risk of LNM (12). However, early CLS has distinct clinicopathological features, depending on the EBV infection status and LNM status (13). CLS had the characteristic histologic type of EBV GC, so we performed EBV-encoded small RNA1 in situ hybridization (EBER1 ISH) for the ESD specimen. Almost all tumor cell nuclei were EBER1-positive, and his second GC lesion was confirmed to be EBV GC (Fig. 3). Retrospectively, his former GC lesion was found to be EBER1-negative.

The present EBV GC lesion was poorly differentiated-type adenocarcinoma invading into the submucosal layer and evaluated as not meeting the extended criteria for ESD in the Japanese Gastric Cancer Treatment Guidelines (9). Be-
Figure 2. ESD for the early EBV GC lesion. Based on the results of the pretherapeutic examination, his GC lesion was considered a candidate for the extended criteria of ESD. a: ESD performance. b: There was no residual tumor after en bloc resection. c: ESD specimen. d: The tumor was located in the red-lined area.

Figure 3. Pathological features of ESD specimen. a: Low-power microscopic picture of Hematoxylin and Eosin staining. The tumor was 10 mm in diameter and invaded 0.8 mm into the submucosal layer. The pathological type was CLS, and lymphovascular infiltration was negative. b: Middle-power microscopic picture of EBER1 ISH. c: High-power microscopic picture of EBER1 ISH. Almost all tumor cell nuclei were positive for EBER1 ISH. The lesion was confirmed to be EBV GC.
cause of the risk of recurrence from possible LNM, we recommended he undergo an additional curative surgical operation with lymph node dissection based on the guidelines. At that time, we also informed him of the reported data concerning the relatively low risk of LNM from early EBV GC. The patient decided not to undergo the surgery or adjuvant chemotherapy. He has been in good health for over three years since ESD without disease recurrence and is being observed using endoscopy and CT.

Discussions

ESD is performed for the local treatment of GC lesions of the stomach, and the criteria for ESD are strictly limited to GC lesions with a very low risk of LNM. Ordinarily, poorly differentiated-type predominant GC with invasion into the submucosal layer has some risk of LNM and is indicated for surgical operation with regional lymph node dissection. Thus, since our present case with a GC lesion of poorly differentiated-type predominant GC with invasion into the submucosal layer was indicated for an additional surgical procedure, we recommended the patient undergo this procedure. However, he did not agree to it and remains in disease-free good health over three years after ESD.

Recently, accumulating data has shown that the risk of LNM from early EBV GC without local lymphovascular infiltration is low. Tokunaga et al. reported that there was no marked incidence of LNM among 75 EBV GC cases compared with 53 instances among 562 EBV-negative GC cases restricted to the mucosa and submucosal layer (7). Park et al. also reported that EBV positivity was a favorable risk factor for LNM in submucosa-invasive early GC (14). They suggested that an examination with EBER ISH should be considered for endoscopically resected specimens, especially in cases of submucosa-invasive early GC showing no lymph vessel invasion and clear resection margins. These reports indicate the possible further extension of the curative ESD criteria for early EBV GC invading into the submucosal layer without local lymphovascular infiltration. A precise examination using special staining is important for evaluating the lymphovascular infiltration of ESD specimens. Indeed, Lee et al. reported favorable outcomes in an early EBV GC case series treated with ESD (15).

In many cases, EBV GC is located in the upper part of the stomach and remnant stomach. Therefore, such extension of the criteria may prevent unnecessarily excessive surgery, such as total gastrectomy.

Conclusions

We herein reported a favorable clinical outcome for over three years of a case of early EBV GC invading the submucosal layer that was treated with ESD. Some cases of early EBV GC with invasion into the submucosal layer may be candidates for the further extension of the ESD criteria. The further accumulation of outcome data on early EBV GC treated with ESD is required in order to prevent possible overtreatment.

Informed consent was obtained from the patient.

The authors state that they have no Conflict of Interest (COI).

References

1. The Cancer, Genome Atlas, Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513: 202-209, 2014.
2. Murphy G, Pfeiffer R, Camargo MC, et al. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology 137: 824-833, 2009.
3. Yanai H, Nishikawa J, Mizugaki Y, et al. Endoscopic and pathologic features of Epstein-Barr virus-associated gastric carcinoma. Gastrointest Endosc 45: 236-242, 1997.
4. Watanabe H, Enjojii M, Imai T, et al. Gastric carcinoma with lymphoid stroma: its morphologic characteristics and prognostic correlations. Cancer 38: 232-243, 1976.
5. Song HJ, Srivastava A, Lee J, et al. Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma. Gastroenterology 139: 84-92, 2010.
6. Yanai H, Yahara N, Furuya T, et al. Long-term survival of patient with Epstein-Barr virus-positive gastric cancer treated with chemotherapy: case report. J Gastrointest Cancer 47: 107-110, 2016.
7. Tokunaga M, Land CE. Epstein-Barr virus involvement in gastric cancer: biomarker for lymph node metastasis. Cancer Epidemiol Biomarkers Prev 7: 449-450, 1998.
8. Bourke MJ, Neuhaus H, Bergman JJ. Endoscopic submucosal dissection: indications and application in western endoscopy practice. Gastroenterology 154: 1887-1900, 2018.
9. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 20: 1-19, 2017.
10. Hatta W, Gotoda T, Oyama T, et al. Is radical surgery necessary in all patients who do not meet the curative criteria for endoscopic submucosal dissection of early gastric cancer? A multi-center retrospective study in Japan. J Gastroenterol 52: 175-184, 2017.
11. Yanai H, Matsubara Y, Kawano T, et al. Clinical impact of strip biopsy for early gastric cancer. Gastrointest Endosc 60: 771-777, 2004.
12. Pyo JH, Lee H, Min BH, et al. Early gastric cancer with a mixed-type Lauren classification is more aggressive and exhibits greater lymph node metastasis. J Gastroenterol 52: 594-601, 2017.
13. Lim H, Lee IS, Lee JH, et al. Clinical application of early gastric carcinoma with lymphoid stroma based on lymph node metastasis status. Gastric Cancer 20: 793-801, 2017.
14. Park JH, Kim EK, Kim YH, et al. Epstein-Bar virus positivity, not mismatch repair-deficiency, is a favorable risk factor for lymph node metastasis in submucosa-invasive early gastric cancer. Gastric Cancer 19: 1041-1051, 2016.
15. Lee JY, Kim KM, Min BH, et al. Epstein-Barr virus-associated lymphoepithelioma-like early gastric carcinomas and endoscopic submucosal dissection: Case series. World J Gastroenterol 20: 1365-1370, 2014.